Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2015

View Archived Issues

Novartis recaps progress of fourth quarter 2014

iCura in-licenses dry AMD program

Combination therapy of repurposed drugs shows promise for Charcot-Marie-Tooth disease

Novel treatment for cocaine addiction TV-1380 safe in healthy subjects

Lisdexamfetamine shows efficacy for treatment of BE disorder

Novavax presents update on development pipeline

Envisia Therapeutics begins phase IIa trial of ENV-515 in patients with glaucoma

CymaBay Therapeutics reports preclinical data for MBX-8025

BrainStorm reports preclinical data for NurOwn in mouse autism model

AgeneBio receives grant to support AGB-101 trial in amnestic mild cognitive impairment

enGene raises funds to develop intestinal gene delivery platform

Meda to transfer Onsolis North American marketing authorizations to BioDelivery Sciences

Advaxis reports update on phase II study of ADXS-HPV

Bayer patents novel Mnk1 inhibitors

GSK reports new EZH2 inhibitors

Ono Pharmaceutical discloses novel lipoxin receptor agonists

Applied Molecular Transport and Janssen establish IBD collaboration

New tyrosine kinase modulators designed at Zhejiang Beta Pharma

Investigators in Spain patent new PPAR agonists

PsychoGenics achieves milestone in Sunovion collaboration

Spark project launched to develop IPR-019 for schizophrenia-associated cognitive impairment

ProMetic receives clearance to start trial of PBI-4050 in metabolic-syndrome-associated diabetes

RegeneRx and G-treeBNT partner to develop RGN-259 in the U.S. for ophthalmic indications

AnaMar announces strategic realignment

Bill & Melinda Gates Foundation pledges commitment to Gavi

European Commission clears GSK's proposed transaction with Novartis

Biogen Idec, Fondazione Telethon and Ospedale San Raffaele collaborate on hemophilia gene therapies

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...